Paul F. Duffy, Managing Principal


Mr.Duffy brings Black Mountain Consulting Group extensive experience at both big  pharma and start-up organizations. He acquired more than 30 years of big pharma experience at Novartis Pharmaceuticals (formerly Sandoz Pharmaceuticals), having held sales and marketing positions of increasing responsibility from 1972 to 2003, when he served as U.S. National Sales Director-Neuroscience.  Mr. Duffy then left Novartis to co-found start-up Alamo Pharmaceuticals, where he  served as Executive Vice President.  At Alamo, he created a fully integrated, national pharmaceutical company to market Fazaclo, a patented reformulation of Novartis' anti-psychotic drug, Clozaril.  Duffy left Alamo in July 2006, after completing its sale to Avanir Pharmaceuticals.  He then became founding CEO of Validus Pharmaceuticals, creating an entirely new type of private-equity backed pharmaceutical company.  Most recently, Duffy served as President, US Commercial Operations for the UK-based multinational, Amarin Pharmaceuticals.  Black Mountain is a result of these collective experiences.

Josh Weinstein, Principal


Josh Weinstein has been formulating creative pharmaceutical marketing solutions since 1968. His particular specialty is translating complex science into marketing claims that are easy to understand and visualize.  Mr. Weinstein's marketing
communications expertise was honed in a career extending from physician and hospital sales, product management, new product development and launches to managing the nation's most successful advocacy and public education campaign.  For the past 12 years, Weinstein has served as President of jwEinstein Strategic Messaging, Inc., a full service advertising, PR and advocacy development company that specializes in helping start-ups and young pharma and device companies to promote, license and launch new technologies and products, as well as re-launch more mature products.  Mr. Weinstein's career began at Sandoz Pharmaceuticals (now Novartis) where he served in numerous field and marketing capacities culminating in the launch campaigns for Tavist and Visken.  Weinstein then joined Schering-Plough where he became Director of Marketing and launched Normodyne and Intron-A (alfa-interferon) which is now a multi-billion dollar product.  After moving to Schering International to manage a developing cardiovascular pipeline, he was recruited by Squibb where, as Vice President of Marketing, he managed their entire US Product line as well the development of Pravachol (one of the nation's first 'statins').

Michael A. Leone, Principal


Mike Leone is recognized as an accomplished pharmaceutical executive with broad therapeutic expertise.  His over 30 years of experience and leadership includes positions of increasing senior level responsibility at Bristol-Myers Squibb, First Horizon
Pharmaceuticals, Eyetech Pharmaceuticals and Takeda Pharmaceuticals North America.  Mike is currently President of Strategic HealthCare Resources, LLC, and is consulting for a number of venture capital, pharmaceutical, biotech and device companies.  He has helped companies create sales force deployment models, developed compensation models, served as a direct customer liaison with state Medicaid and federal government customers on formulary and pharmacoeconomic issues, consulted on clinical trial focus areas, conducted focused leadership training programs, and counseled a growing sales organization on how to enhance the structure of its organization and improve the capabilities of its leaders.  Having spent the majority of his career at Bristol-Myers Squibb, Mr. Leone held numerous positions of increasing responsibility.  These positions included National Director, Federal & Institutional Sales, aposition in which he rebuilt the Hospital Sales Team and strengthened BMS' role and commitment to VA and military customers.  In that role,
Mike spearheaded the institutional launches of Maxipime and Plavix.  Mike's National Accounts experience, and focused, field-based hospital sales leadership expertise have made him an especially valuable asset to Specialty Pharma clients.